首页> 外文期刊>Current vascular pharmacology >Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
【24h】

Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?

机译:降低药物对动脉僵硬的影响:一种降低心血管风险的一种方法吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Arterial stiffness (AS) is considered an independent predictor of cardiovascular disease (CVD) events. Among lipid lowering drugs, statins have a beneficial effect on AS, independent of their hypolipidaemic effect. Based on 3 meta-analyses and other studies, this effect is compound- and dose-related. Potent statins at high doses are more effective than less powerful statins. Ezetimibe (+/- statin) also seems to decrease AS in patients with dyslipidaemia. Fibrates have no effect on AS. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have data that beneficially affect all AS risk factors, suggesting a beneficial effect on artery compliance. However, there is no direct measurement of their effect on AS indices. In patients with dyslipidaemia, prescribing high dose statins (+/- ezetimibe) will not only decrease low-density lipoprotein cholesterol levels but also improve AS (in addition to other effects). This effect on AS may contribute to the observed reduction in vascular events.
机译:动脉僵硬(AS)被认为是心血管疾病(CVD)事件的独立预测因子。在脂质降低药物中,他汀类药物对其具有效果的效果,与其血肿性效应无关。基于3个荟萃分析和其他研究,这种效果是复合和剂量相关的。高剂量下的有效的他汀类药物比强有力的毒素更有效。 ezetimibe(+/- statin)似乎在患有血脂血症患者中的降低。匹配对此没有影响。 ProProtein转化酶枯草杆菌蛋白酶/ kexin型9(PCSK9)抑制剂具有有益地影响所有风险因素的数据,这表明对动脉遵从的有益影响。但是,没有直接测量它们对指数的影响。在患有血脂血症的患者中,处方高剂量毒素(+/- ezetimibe)不仅会降低低密度脂蛋白胆固醇水平,而且还可以改善(除其他作用)。这种效果可能导致观察到的血管事件的减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号